Russian pharmaceutical market size in 2016 reached 1,344 billion rubles, which is 7% higher than a year earlier, and in 2017 reached 1,629 billion rubles, which is 8% higher than in 2016.
Drug sales in physical terms increased by 6% to 6.3 billion packs. The positive dynamics in packages in 2017 indicate an improvement in the purchasing power of the population and the reduced impact of financial and economic factors on the pharmaceutical market.
The main contribution to market growth was made by the commercial segment of drugs. The dynamics of
the retail market continued the positive trend of 2016 in packages. Market growth in rubles is lower than in 2016. This was influenced, among other things, by the low incidence of influenza and acute respiratory viral infections, which did not lead to an increase in demand for “seasonal” drugs.
The main two trends in drug consumption are the increase in the share of domestic drugs and consumer switching to generics (generic drug – a drug sold under an international non-proprietary name or a proprietary name different from the brand name of the developer of the drug.
The increase in the commercial drug market in 2018 relative to 2017 in ruble equivalent was 4.6%.
Compared to December 2017, this year the market showed a 6.7% increase in sales. The average cost of drug units in the commercial market of Russia increased by 2.1% in December compared to November and amounted to 197.9 rubles.
The structure of the commercial drug market in December 2018 by price segments has changed in favor of drugs of high price segment compared to the same period of 2017.
The share of the group of drugs under 50 rubles decreased by 0.3% relative to December 2017 and amounted to 4.6%. The share of the segment of drugs with an average package price of 50-150 rubles was 10.3% (-0.3%). The share of the group of drugs with the price range “150-500 rubles” decreased from 46.7% in December 2017 to 44.9% in December 2018. The share of expensive drugs was 40.2%, which is 2.4% higher than the weight of the group in the previous year.
At the end of December 2018. 58.9% of drugs sold on the market were domestic (in physical units), however, due to their low price relative to imported drugs in value terms, they took 29.8%.
The ranking of companies by value sales in December 2018 was headed by Bayer, second place went to Sanofi-Aventis, and third place to Novartis.
The top 3 drug brands by the value of pharmacy sales in Russia in December 2018 consisted of such drugs as Kagocel (1.0%) and Xarelto (0.8%); in third place was Nurofen (0.7%).
The volume of the commercial drug market in January 2019 amounted to 84.3 billion rubles. (in retail prices). Compared to January 2018 this year the market showed an increase in sales by 7.9%.
The structure of the commercial drug market in January 2019 by price segment changed in favor of high price segment drugs compared to the same period of 2018.
The share of the group of drugs under 50 rubles decreased by 0.4% relative to January 2018 and amounted to 4.4%. The share of the segment of drugs with an average package price of 50-150 rubles was 11.3% (-0.4%). The share of the group of drugs with a price range of 150-500 rubles decreased from 44.4% in January 2018 to 43.9% in January 2019. The share of expensive drugs was 40.4%, which is 1.3% higher than in the previous year.
At the end of January 2019. 58.8% of drugs sold on the market were domestic (in physical units), however, due to their low price relative to imported drugs, they took 29.9% in value terms.
The ranking of companies by value sales in January 2019 was headed by Novartis, in second place – Bayer, in third place – Sanofi.
The top 3 among drug brands by pharmacy sales value in Russia in January 2019 consisted of such drugs as Kagocel (1.0%), Inhavirin (0.9%); in third place was Nurofen (0.7%).
DSM group annual report 2016
DSM group annual report 2017
DSM group annual report 2018
DSM group annual report 2019